Xeris Biopharma Holdings Inc XERS
$8.70 $0.10 (1.16%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
XERS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Xeris Biopharma Holdings Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Xeris Biopharma Holdings Inc. Stock Analysis XERS
United States Health Care Small Cap Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Xeris Biopharma Holdings Inc (XERS) Chart
Financial Metrics & Statements of Xeris Biopharma Holdings Inc (XERS)
FAQ's for Xeris Biopharma Holdings Inc (XERS)
- As of August 2026, Xeris Biopharma Holdings Inc XERS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Xeris Biopharma Holdings Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Xeris Biopharma Holdings Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Xeris Biopharma Holdings Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Xeris Biopharma Holdings Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Xeris Biopharma Holdings Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Xeris Biopharma Holdings Inc (XERS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
